Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome

被引:53
|
作者
Baroutis, G [1 ]
Kaleyias, J [1 ]
Liarou, T [1 ]
Papathoma, E [1 ]
Hatzistamatiou, Z [1 ]
Costalos, C [1 ]
机构
[1] Gen Dist Hosp Alexandra, Dept Neonatal Med, Athens, Greece
关键词
surfactant; respiratory distress syndrome; Alveofact; Poractant; Beractant;
D O I
10.1007/s00431-002-1144-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim of the study was to compare the treatment regimen of three natural surfactants of different extraction and formulation (Alveofact [Surfactant A = SA], Poractant [Surfactant B = SB] and Beractant [Surfactant C = SC]) in neonatal respiratory distress syndrome (RDS). Premature infants of less than or equal to32 weeks' gestation with birth weight of less than or equal to2,000 g and with established RDS requiring artificial ventilation with a FiO2 greater than or equal to0.3 were randomly assigned to receive at least two doses of SA, SB or SC (100 mg/kg per dose). Infants who remained dependent on artificial ventilation with a FiO2 greater than or equal to0.3 received up to two additional doses. There were no differences among the groups regarding the necessity for more than two doses. The SA and the SB groups spent fewer days on a ventilator (p-value SA/SB 0.7, SA/SC 0.05, SB/SC 0.043) compared with the SC group, needed fewer days of oxygen administration (p-value SA/SB 0.14, SA/SC 0.05, SB/SC 0.04) and spent fewer days in hospital (p-value SA/SB 0.65, SA/SC 0.04, SB/SC 0.027). There were no statistically significant differences in the incidence of mortality, chronic lung disease, air leaks, necrotising enterocolitis, retinopathy of prematurity and intraventricular haemorrhage among the three groups. Conclusion: the Alveofact and Poractant groups spent fewer days on the ventilator, needed fewer days of oxygen administration and spent fewer days in hospital compared with the Beractant group but no differences were observed among the three groups with regards to mortality and morbidity.
引用
收藏
页码:476 / 480
页数:5
相关论文
共 50 条
  • [41] Evaluation Of A Synthetic Lung Surfactant For Neonatal Respiratory Distress Syndrome
    Ernst, W.
    Do, T.
    Chiang, S.
    Ward, R.
    Heldt, G.
    Fujii, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [42] Surfactant protein A and inflammatory cytokines in neonatal respiratory distress syndrome
    Beresford, MW
    Shaw, NJ
    THORAX, 2000, 55 : A19 - A19
  • [43] Surfactant for respiratory distress syndrome: are there important clinical differences among preparations?
    Sinha, Sunil
    Moya, Fernando
    Donn, Steven M.
    CURRENT OPINION IN PEDIATRICS, 2007, 19 (02) : 150 - 154
  • [44] Early Immunomodulatory Effects of Different Natural Surfactant Preparations in Preterms With Respiratory Distress
    Yalaz, Mehmet
    Tanriverdi, Sema
    Uygur, Ozgun
    Koroglu, Ozge Altun
    Azarsiz, Elif
    Aksu, Guzide
    Kultursay, Nilgun
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [45] Exogenous Natural Surfactant for Treatment of Acute Lung Injury and the Acute Respiratory Distress Syndrome
    Kesecioglu, Jozef
    Beale, Richard
    Stewart, Thomas E.
    Findlay, George P.
    Rouby, Jean-Jacques
    Holzapfel, Laurent
    Bruins, Peter
    Steenken, Edmee J.
    Jeppesen, Ole K.
    Lachmann, Burkhard
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (10) : 989 - 994
  • [46] NATURAL SURFACTANT AEROSOLIZATION IN ADULT-RESPIRATORY-DISTRESS-SYNDROME
    DOCAMPO, JL
    TURCHETTO, E
    BERTRANOU, EG
    HAGER, A
    DEPAOLI, T
    LANCET, 1994, 344 (8919): : 413 - 414
  • [47] Choosing a Right Surfactant for Respiratory Distress Syndrome Treatment
    Ramanathan, Rangasamy
    NEONATOLOGY, 2009, 95 (01) : 1 - 5
  • [48] RESPIRATORY-DISTRESS - PAF AND SURFACTANT PREPARATIONS
    CAPLAN, MS
    LANCET, 1993, 341 (8849): : 865 - 866
  • [49] Surfactant lavage treatment in a model of respiratory distress syndrome
    Cochrane, CG
    Revak, SD
    CHEST, 1999, 116 (01) : 85S - 86S
  • [50] Which surfactant for treatment of respiratory-distress syndrome
    Jobe, AH
    LANCET, 2000, 355 (9213): : 1380 - 1381